Skip to main content Skip to secondary navigation

Docket #: S20-279

A Three Component Vaccine for Covid-19

Stanford researchers have designed a vaccine for COVID-19 that induces isotype switched neutralizing antibody responses. The vaccine is comprised of three parts: a mRNA encoding the soluble version of the Receptor Binding Domain (RBD) of SARS-CoV-2 Spike protein, a TLR9 agonist (CpG) and Charge Altering Releasable Transporters (CARTs). RBD mRNA and TLR9 agonist are delivered to cells in living animals using CARTs to efficiently formulate nanoparticles around the components. In vivo data demonstrates that the three-component vaccine induces robust anti-RBD immunoglobulin response.

Related technology: Stanford Docket S16-157: "CART – a transfection delivery system for efficient intracellular mRNA delivery"

Stage of Research

  • in vivo
  • Applications

    • COVID-19 vaccine
    • Other viral vaccines

    Advantages

    • mRNA vaccine with TLR9 agonists
    • Easily adapted to other viruses by swapping protein
    • CART tailors bioavailability to lungs, other organs or systems

    Publications

    Patents

    Similar Technologies

    Explore similar technologies by keyword: